Evidence map›Paper›PMID 41632032›Full record

ReviewEndocrine reviews2026

Vitamin D and Uterine Fibroids: Insights into Pathophysiology and Therapeutic Potential.

Michał Ciebiera, Elżbieta Zarychta, Natalia Żeber-Lubecka, Magdalena Zgliczyńska, Marta Włodarczyk, Diana Massalska, Ana Corachán, Mohamed Ali, Obianuju Sandra Madueke-Laveaux, Ayman Al-Hendy

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrine reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michał CiebieraSecond Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, Warsaw Institute of Women's Health, Warsaw 00-189, Poland.
Elżbieta ZarychtaSecond Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, Warsaw Institute of Women's Health, Warsaw 00-189, Poland.ORCID 0000-0003-0237-6899
Natalia Żeber-LubeckaDepartment of Gastroenterology, Hepatology and Clinical Oncology, Center of Postgraduate Medical Education, Warsaw 02-781, Poland.
Magdalena ZgliczyńskaDepartment of Obstetrics, Perinatology and Neonatology, Center of Postgraduate Medical Education, Warsaw 01-809, Poland.
Marta WłodarczykDepartment of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, Warsaw 02-097, Poland.
Diana MassalskaSecond Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, Warsaw Institute of Women's Health, Warsaw 00-189, Poland.
Ana CorachánIVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe, Valencia 46026, Spain.
Mohamed AliDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Obianuju Sandra Madueke-LaveauxDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Ayman Al-HendyDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.

Funding

Center of Postgraduate Medical Education 501-1-022-26-24Center of Postgraduate Medical Education 501-1-022-26-24)Center of Postgraduate Medical Education 501-1-022-26-25National Institute of Health R01 ES 028615National Institute of Health R01HD 087417National Institute of Health R01 HD 094378National Institute of Health R01 HD 094380
6 · The paper itself

Abstract

Uterine fibroids (UFs) are highly prevalent benign tumors, primarily affecting women of reproductive age. The prevalence of UFs is estimated at 25% to 70% to 80%, with significantly higher rates among African women. Recent investigations have unveiled a link between vitamin D (VD) levels and the presence of UFs. Current data show that individuals with sufficient VD levels are at a reduced risk of developing UFs. This review aims to synthesize the latest discoveries on the involvement of VD in the pathophysiology of UFs, as well as to explore its feasible therapeutic applications. The mechanisms underlying the potential of VD to diminish the risk of UF development and to inhibit their growth are multifaceted and include its antiproliferative effects, the induction of apoptosis, suppression of angiogenesis, or the modulation of enzyme activity. The potential of VD and its analogues as promising agents for managing and preventing UFs was demonstrated. However, further research is needed to clarify the biological mechanisms behind the role of VD in UF pathophysiology, and its definitive efficacy has to be confirmed through randomized clinical trials.

Indexed as

LeiomyomaUterine NeoplasmsVitamin DAnimalsFemaleHumansVitamin D DeficiencyVitamin Dleiomyomapathophysiologyuterine fibroidsvitamin D

Identifiers

PMID41632032
PMCPMC13167191

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.